[go: up one dir, main page]

EE200200550A - Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine - Google Patents

Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine

Info

Publication number
EE200200550A
EE200200550A EEP200200550A EEP200200550A EE200200550A EE 200200550 A EE200200550 A EE 200200550A EE P200200550 A EEP200200550 A EE P200200550A EE P200200550 A EEP200200550 A EE P200200550A EE 200200550 A EE200200550 A EE 200200550A
Authority
EE
Estonia
Prior art keywords
caspase inhibitors
carbamate
carbamate caspase
inhibitors
caspase
Prior art date
Application number
EEP200200550A
Other languages
English (en)
Estonian (et)
Inventor
Bebbington David
Charrier Jaen-Damien
Kay David
Knegtel Ronald
Golec Julian
Mortimore Michael
Studley John
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of EE200200550A publication Critical patent/EE200200550A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/30—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with acyl radicals attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
EEP200200550A 2000-03-29 2001-03-29 Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine EE200200550A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19282600P 2000-03-29 2000-03-29
PCT/US2001/010182 WO2001072707A2 (en) 2000-03-29 2001-03-29 Carbamate caspase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
EE200200550A true EE200200550A (et) 2004-02-16

Family

ID=22711181

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200550A EE200200550A (et) 2000-03-29 2001-03-29 Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine

Country Status (32)

Country Link
US (2) US6689784B2 (es)
EP (1) EP1268425B1 (es)
JP (2) JP4298200B2 (es)
KR (1) KR100858640B1 (es)
CN (2) CN100358869C (es)
AR (1) AR027993A1 (es)
AT (1) ATE384695T1 (es)
AU (2) AU4961901A (es)
BG (1) BG107136A (es)
BR (1) BR0109588A (es)
CA (1) CA2403959A1 (es)
CZ (1) CZ20023227A3 (es)
DE (1) DE60132567T2 (es)
DK (1) DK1268425T3 (es)
EA (1) EA005740B1 (es)
EE (1) EE200200550A (es)
ES (1) ES2296742T3 (es)
HK (1) HK1052355B (es)
HR (1) HRP20020782A2 (es)
HU (1) HUP0301472A3 (es)
IL (2) IL151829A0 (es)
MX (1) MXPA02009633A (es)
NO (1) NO325062B1 (es)
NZ (1) NZ521639A (es)
PE (1) PE20011267A1 (es)
PL (1) PL201081B1 (es)
PT (1) PT1268425E (es)
SK (1) SK13922002A3 (es)
TW (1) TWI318207B (es)
WO (1) WO2001072707A2 (es)
YU (1) YU73702A (es)
ZA (1) ZA200207483B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4213500A (en) 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
WO2001016093A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20040192889A1 (en) * 2001-03-30 2004-09-30 Dale Bredesen Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
CA2447999C (en) 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2003211052A1 (en) * 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (en) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
US20060217299A1 (en) * 2003-02-24 2006-09-28 Hirofumi Doi Degradation inhibitor for hepatitis b virus x interacting protein
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
JP4898658B2 (ja) * 2004-03-12 2012-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
CN102362867A (zh) * 2004-05-15 2012-02-29 沃泰克斯药物股份有限公司 使用ice抑制剂治疗癫痫发作
KR100619440B1 (ko) 2004-05-20 2006-09-08 한기종 포름아마이드 유도체 제조방법
KR100619439B1 (ko) 2004-05-27 2006-09-08 한기종 포밀기 도입된 아민유도체의 제조방법
US8012751B2 (en) * 2005-03-31 2011-09-06 Wisconsin Alumni Research Foundation Differentiation of pluripotent embryonic stem cells
CA2616337A1 (en) * 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
CN101278598B (zh) 2005-10-07 2011-05-25 松下电器产业株式会社 音频信号处理装置以及音频信号处理方法
CN101511169A (zh) 2005-11-30 2009-08-19 麻省理工学院 病原体检测细胞保存系统
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
WO2008008264A2 (en) * 2006-07-07 2008-01-17 The Board Of Trustees Of The Leland Stanford Junior University Selective caspase inhibitors
WO2008021745A2 (en) * 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
US8828950B2 (en) * 2007-05-01 2014-09-09 Cedars-Sinai Medical Center Caspase inhibitors in the treatment of infection-associated preterm delivery
KR101009588B1 (ko) * 2008-06-04 2011-01-20 거진산업주식회사 미세여과막을 이용한 부유고형물 처리장치
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
KR101010350B1 (ko) * 2009-03-26 2011-01-25 삼성중공업 주식회사 역세척 여과장치
EP2635906A4 (en) 2010-11-05 2014-04-02 Univ Brandeis Ice inhibiting compounds and uses thereof
TW201236239A (en) * 2010-11-16 2012-09-01 Solvay Rechargeable metal or metal-ion cell
EP2490021A1 (en) 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
AU2015259471A1 (en) 2014-05-12 2016-11-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US20190022043A1 (en) 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
US12173350B2 (en) * 2017-05-24 2024-12-24 Ramot At Tel-Aviv University Ltd. Chemiluminescent probes for imaging/detection of proteases
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
NZ334605A (en) 1996-09-12 2000-08-25 Idun Pharmaceuticals Inc C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and for treatments of inflammatory, autoimmune, neurodegenerative disorders and in the prevention of ischemic injury
NZ334906A (en) * 1996-10-11 2000-09-29 Basf Ag A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor
JP2001506974A (ja) 1996-10-11 2001-05-29 ワーナー―ランバート・コンパニー インターロイキン―１β変換酵素のアスパルテートエステル阻害剤
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
WO1999018781A1 (en) 1997-10-10 1999-04-22 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
DE69925268T2 (de) 1998-03-16 2006-03-23 Cytovia, Inc., San Diego Dipeptid-Caspase-Inhibitoren und deren Verwendung
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR20010110667A (ko) 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
AU4213500A (en) 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
WO2001016093A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
PL358430A1 (en) 2004-08-09
ZA200207483B (en) 2003-09-18
SK13922002A3 (sk) 2003-09-11
ES2296742T3 (es) 2008-05-01
AR027993A1 (es) 2003-04-23
WO2001072707A3 (en) 2002-05-23
JP4298200B2 (ja) 2009-07-15
KR20020086711A (ko) 2002-11-18
DE60132567T2 (de) 2009-01-22
MXPA02009633A (es) 2003-03-10
NO325062B1 (no) 2008-01-28
US6689784B2 (en) 2004-02-10
KR100858640B1 (ko) 2008-09-17
YU73702A (sh) 2006-03-03
US7074782B2 (en) 2006-07-11
PE20011267A1 (es) 2001-12-15
PL201081B1 (pl) 2009-03-31
CN1994298A (zh) 2007-07-11
NO20024661D0 (no) 2002-09-27
WO2001072707A2 (en) 2001-10-04
HUP0301472A2 (hu) 2003-08-28
HK1052355B (en) 2008-06-27
EP1268425A2 (en) 2003-01-02
HRP20020782A2 (en) 2004-12-31
BG107136A (bg) 2003-05-30
ATE384695T1 (de) 2008-02-15
CA2403959A1 (en) 2001-10-04
AU4961901A (en) 2001-10-08
EA200201030A1 (ru) 2003-02-27
DK1268425T3 (da) 2008-05-05
HK1052355A1 (en) 2003-09-11
HUP0301472A3 (en) 2005-04-28
US20040053920A1 (en) 2004-03-18
NZ521639A (en) 2004-05-28
EP1268425B1 (en) 2008-01-23
PT1268425E (pt) 2008-04-01
CN1422253A (zh) 2003-06-04
CZ20023227A3 (cs) 2003-01-15
TWI318207B (en) 2009-12-11
IL151829A0 (en) 2003-04-10
US20020028803A1 (en) 2002-03-07
DE60132567D1 (de) 2008-03-13
AU2001249619B2 (en) 2006-08-17
EA005740B1 (ru) 2005-06-30
BR0109588A (pt) 2003-02-04
JP2008266348A (ja) 2008-11-06
JP2003528855A (ja) 2003-09-30
NO20024661L (no) 2002-11-26
CN100358869C (zh) 2008-01-02
IL151829A (en) 2012-03-29

Similar Documents

Publication Publication Date Title
EE200200550A (et) Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
ID30590A (id) Celana sekali pakai jenis-celana pendek
DE50112013D1 (de) Deodorantien und antiperspirantien
EP1412378A4 (en) APTAMERS AND ANTIAPTAMERS
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
NO20024099L (no) Lavdose entecavir-formulering og anvendelse
PT1326853E (pt) Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
EE200300247A (et) Isotiasool-4-karboksamiidi soolad ja nende kasutamine hüperproliferatsioonivastaste vahenditena
DE60139763D1 (de) Lanzen und -tieren
IS6822A (is) Imidazól- og bezimidazól kaspasatálmar og notkun þeirra
NO20025510L (no) Dibenzoazulen-derivater samt anvendelse derav
DE50104507D1 (de) Reinigungs- und desinfektionsmittel
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
NO20024617D0 (no) Aryl- og heteroarylsulfonater
EE200200557A (et) Sünergistilised herbitsiidsed meetodid ja segud
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö
NO20025135L (no) Antihypertensive midler og anvendelse
DE60219418D1 (de) Silanylphenole und -naphthole
SE0002629D0 (sv) Novel compounds and their use